$43.03
0.12% yesterday
Nasdaq, Aug 01, 10:00 pm CET
ISIN
US4622221004
Symbol
IONS

Ionis Pharmaceuticals, Inc. Stock price

$43.03
+3.09 7.74% 1M
+10.90 33.92% 6M
+8.07 23.08% YTD
-8.29 16.15% 1Y
+5.54 14.78% 3Y
-16.16 27.30% 5Y
-10.93 20.26% 10Y
+38.36 821.41% 20Y
Nasdaq, Closing price Fri, Aug 01 2025
+0.05 0.12%
ISIN
US4622221004
Symbol
IONS
Industry

Key metrics

Basic
Market capitalization
$6.9b
Enterprise Value
$6.0b
Net debt
positive
Cash
$2.1b
Shares outstanding
159.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
9.6 | 8.9
EV/Sales
8.3 | 7.7
EV/FCF
negative
P/B
14.4
Financial Health
Equity Ratio
19.6%
Return on Equity
-77.2%
ROCE
-18.4%
ROIC
-85.3%
Debt/Equity
2.6
Financials (TTM | estimate)
Revenue
$717.3m | $770.1m
EBITDA
$-450.7m | $-514.1m
EBIT
$-472.4m | $-488.0m
Net Income
$-458.0m | $-500.4m
Free Cash Flow
$-555.2m
Growth (TTM | estimate)
Revenue
-7.6% | 9.2%
EBITDA
-23.6% | -13.5%
EBIT
-24.3% | -2.7%
Net Income
-19.0% | -10.2%
Free Cash Flow
-62.7%
Margin (TTM | estimate)
Gross
98.5%
EBITDA
-62.8% | -66.8%
EBIT
-65.9%
Net
-63.9% | -65.0%
Free Cash Flow
-77.4%
More
EPS
$-2.9
FCF per Share
$-3.5
Short interest
10.8%
Employees
1k
Rev per Employee
$660.0k
Show more

Is Ionis Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,028 stocks worldwide.

Ionis Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

32 Analysts have issued a Ionis Pharmaceuticals, Inc. forecast:

23x Buy
72%
8x Hold
25%
1x Sell
3%

Analyst Opinions

32 Analysts have issued a Ionis Pharmaceuticals, Inc. forecast:

Buy
72%
Hold
25%
Sell
3%

Financial data from Ionis Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
717 717
8% 8%
100%
- Direct Costs 11 11
6% 6%
1%
707 707
8% 8%
99%
- Selling and Administrative Expenses 291 291
22% 22%
41%
- Research and Development Expense 888 888
3% 3%
124%
-451 -451
24% 24%
-63%
- Depreciation and Amortization 22 22
42% 42%
3%
EBIT (Operating Income) EBIT -472 -472
24% 24%
-66%
Net Profit -458 -458
19% 19%
-64%

In millions USD.

Don't miss a Thing! We will send you all news about Ionis Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ionis Pharmaceuticals, Inc. Stock News

Positive
The Motley Fool
2 days ago
Ionis Pharmaceuticals (IONS -0.44%), a biotechnology company focused on RNA-targeted therapeutics, reported its second quarter 2025 earnings on July 30, 2025. The headline news was a substantial beat on both GAAP revenue and non-GAAP earnings compared to Wall Street estimates.
Neutral
Seeking Alpha
3 days ago
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q2 2025 Earnings Conference Call July 30, 2025 11:30 AM ET Company Participants Brett P. Monia - Founder, CEO & Director D.
Neutral
Business Wire
3 days ago
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the second quarter ended June 30, 2025. “During the second quarter, we continued to build momentum across our business,” said Brett P. Monia, Ph.D., chief executive officer of Ionis. “Our strong performance included excellent commercial exec...
More Ionis Pharmaceuticals, Inc. News

Company Profile

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.

Head office United States
CEO Brett Monia
Employees 1,069
Founded 1989
Website www.ionis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today